![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, Biocon will undertake the responsibility of obtaining regulatory approval, manufacturing and supply of Saxenda (liraglutide), used in the treatment of chronic weight management, and Medix will be responsible for its commercialization in the Mexican market.
Lead Product(s): Liraglutide
Therapeutic Area: Nutrition and Weight Loss Product Name: Saxenda-Generic
Highest Development Status: Phase IVProduct Type: Peptide
Partner/Sponsor/Collaborator: Biocon
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 13, 2024